☆ 4.6 Review

Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing

CANCER TREATMENT REVIEWS (2024)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma

Youngsic Jeon et al.

Summary: In this study, we performed an integrative analysis of transcriptome profiles associated with radiopathologic features to identify four subtypes of primary liver cancers (LCs). Our findings revealed intermediate subtypes between hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), and provided insights into their molecular spectrum and progression mechanisms.

HEPATOLOGY (2023)

Add to Collection

Article Oncology

Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience

Matteo Repetto et al.

Summary: Precision oncology aims to improve clinical outcomes by personalizing treatment options for cancer patients. Utilizing ESCAT allows evidence-based evaluation of genomic findings for treatment selection. Molecular tumor boards provide the multidisciplinary expertise necessary for ESCAT evaluation and strategic treatment choice.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Gastroenterology & Hepatology

Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma

Gajanan Kendre et al.

Summary: This study retrospectively analyzed the genomic data of 6,130 patients diagnosed with intrahepatic cholangiocarcinoma (iCCA), and identified seven oncogenic driver genes and their co-mutational patterns. The study also discovered genetic variations and genomic patterns associated with iCCA, which are important for developing effective treatment strategies and predicting mechanisms of resistance.

JOURNAL OF HEPATOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Lipika Goyal et al.

Summary: In this study, 103 patients with FGFR2-altered intrahepatic cholangiocarcinoma were treated with futibatinib for a median duration of 17.1 months. The results showed that futibatinib treatment could effectively inhibit tumor growth, improve survival, and maintain quality of life for patients.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Pathology

First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma

Olaf Neumann et al.

Summary: This study reports the presence of druggable genetic lesions, including FGFR2 gene fusions, in intrahepatic cholangiocarcinoma. The reliable and accurate detection of these fusions using targeted RNA-based next-generation sequencing (NGS) and fluorescence in situ hybridisation (FISH) is discussed. The study highlights the limitations and challenges in detecting FGFR2 fusions and suggests the superiority of fusion partner agnostic approaches in identifying unknown fusion partners.

JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2023)

Add to Collection

Article Oncology

Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre

Alexander Scheiter et al.

Summary: This study evaluated the outcomes of molecular tumor boards in a comprehensive cancer center. The results showed that the recommendation rate was lower for colorectal cancer and pancreatic cancer, indicating the need for a weighted prioritization of different cancers and the implementation of high-tier recommendations.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Review Pathology

Structure and content of the EU-IVDR Current status and implications for pathology

Andy Kahles et al.

Summary: The EU has introduced new regulations for in vitro diagnostic medical devices, which provide guidance for pathology departments but also have gaps and ambiguities that require professional expertise for successful implementation and use.

PATHOLOGIE (2023)

Add to Collection

Review Oncology

Pathology of Cholangiocarcinomas

Nathalie Guedj

Summary: Cholangiocarcinomas are heterogeneous tumors that arise from epithelial cells of the biliary tract and represent the second primary liver malignancy. They can be classified into intrahepatic, perihilar, and distal cholangiocarcinomas. Intrahepatic cholangiocarcinomas are further divided into small duct and large duct types, each with distinct risk factors, gross aspect, histopathological and molecular features, and therapeutic management. Biopsy plays a role in confirming the diagnosis and ruling out other conditions.

CURRENT ONCOLOGY (2023)

Add to Collection

Article Oncology

ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma

Helena Verdaguer et al.

Summary: Cholangiocarcinomas are highly heterogeneous at the molecular level. The classification of actionable molecular alterations according to ESCAT is associated with survival in cholangiocarcinoma patients.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Genetics & Heredity

Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)

Peter Horak et al.

Summary: Professional societies have published guidelines for the clinical interpretation of somatic variants, but they lack a direct, systematic, and comprehensive set of standards and rules for classification. This leads to inconsistent classification and affects patient care, emphasizing the need for addressing this issue.

GENETICS IN MEDICINE (2022)

Add to Collection

Article Pathology

The emerging roles of NGS in clinical oncology and personalized medicine

Bashdar Mahmud Hussen et al.

Summary: Next-generation sequencing (NGS) has become increasingly popular in genomics studies due to advancements in sequencing technology. It is now being utilized in clinical oncology to improve cancer therapy through various approaches, including finding cancer mutations, identifying carriers of these mutations, and implementing personalized medicine. Personalized medicine has the potential to reduce medical expenses by shifting towards an individualized preventive and predictive approach. NGS can accelerate early disease diagnosis and discover pharmacogenetic markers that aid in personalized therapies. Additionally, NGS provides a more comprehensive understanding of cancer and uncovers pathways of cancer development.

PATHOLOGY RESEARCH AND PRACTICE (2022)

Add to Collection

Review Oncology

Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach

May T. Cho et al.

Summary: Cholangiocarcinoma is a rare and poor prognosis cancer, and biomarker testing plays a crucial role in personalized treatment for these patients. However, there are several barriers to the widespread adoption of precision medicine in cholangiocarcinoma patients, including lack of awareness of the importance of biomarker testing, challenges in tissue acquisition, and ineffective collaboration among multidisciplinary teams. Experts from UC Davis and UC Irvine identified gaps in standard practices and recommended best practices to overcome these barriers.

CANCERS (2022)

Add to Collection

Article Health Care Sciences & Services

Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe

Denis Horgan et al.

Summary: Next-generation sequencing (NGS) has the potential to revolutionize cancer treatment with its personalized approach. However, the implementation of NGS in Europe varies, highlighting the need for collaboration among stakeholders. To address this issue, the European Alliance for Personalised Medicine (EAPM) established expert panels consisting of key stakeholders from 10 European countries. The panels identified challenges related to NGS demand and supply, and made recommendations for multi-stakeholder collaboration to improve patient care.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study

Do-Youn Oh et al.

Summary: In patients with advanced biliary tract cancer, gemcitabine and cisplatin plus immunotherapy showed promising efficacy and acceptable safety, with an objective response rate of 66%. The most common adverse events were hematological, with no unexpected safety events observed.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Promising Genomic Testing for Biliary Tract Cancer Using Endoscopic Ultrasound-Guided Fine-Needle Aspiration/Biopsy Specimens

Masaki Kuwatani et al.

Summary: The poor prognosis of biliary tract cancer is due to the challenges in detecting cancer lesions and the lack of standard screening methods. Genomic analysis has shown promise in improving the accuracy of diagnosis for biliary tract cancer, and future diagnosis and treatment should be based on molecular and genetic analysis.

DIAGNOSTICS (2022)

Add to Collection

Review Health Care Sciences & Services

FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint

Filippo Cappello et al.

Summary: This review provides an overview of the application of NGS in molecular diagnostics and discusses the technical issues and challenges associated with its incorporation in pathology diagnostics.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Add to Collection

Letter Oncology

Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe

A. Lamarca et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

J. Pascual et al.

Summary: Circulating tumour DNA (ctDNA) assays conducted on plasma are proving to be valuable tools for identifying actionable mutations in patients with advanced cancer and for detecting molecular residual disease or relapse in early-stage cancer. However, tissue-based testing is still preferred due to the limitations of ctDNA assays.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing

Olaf Neumann et al.

Summary: This study provides a detailed analysis of the genetic characteristics and detection methods of FGFR2 fusion genes in cholangiocarcinoma, as well as suggestions for parameters to be included in molecular diagnostic reports. It aims to support clinicians in decision-making and treatment selection.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Review Oncology

An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma

David C. Madoff et al.

Summary: This article outlines best practices and recommendations from a multidisciplinary team of experts to assist physicians involved in the care of patients with intrahepatic cholangiocarcinoma. It highlights the importance of biomarker testing in iCCA and the challenges associated with it, as well as suggesting best practices for optimizing tissue collection and biomarker testing.

ONCOLOGIST (2022)

Add to Collection

Article Oncology

Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations

K. Murugesan et al.

Summary: This study investigated the landscape of FGFR1-4 genomic alterations in various cancers and analyzed their associations with other genomic markers. The results showed that FGFR mutations in different cancers were associated with different mutational burdens and genomic co-mutations. These findings can help stratify patients in clinical trials and guide treatment.

ESMO OPEN (2022)

Add to Collection

Review Oncology

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis

Estela Sanchez-Herrero et al.

Summary: This article provides an overview of the biological features of circulating tumor DNA (ctDNA), including size, structure, shedding and clearance mechanisms, as well as the pathological factors that determine ctDNA levels. A better understanding of ctDNA biology is crucial for the development of new methods for ctDNA analysis.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Target Enrichment Approaches for Next-Generation Sequencing Applications in Oncology

Rajesh R. Singh

Summary: Screening for genomic sequence variants is crucial in precision medicine and next-generation sequencing technologies have become the preferred platforms due to their capacity for massively parallel sequencing. Targeted NGS workflow involves enrichment of the regions of interest, improving the accuracy and cost-effectiveness of screening.

DIAGNOSTICS (2022)

Add to Collection

Review Oncology

Role of molecular genetics in the clinical management of cholangiocarcinoma

N. Normanno et al.

Summary: The incidence and mortality of cholangiocarcinoma (CCA) have been increasing, and most patients are diagnosed with advanced or metastatic disease. Treatment options for unresectable CCA are limited, but recent identification of targetable genomic alterations has expanded treatment options. Early and accurate diagnosis is crucial for optimizing patient outcomes.

ESMO OPEN (2022)

Add to Collection

Article Oncology

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer

J. E. Berchuck et al.

Summary: cfDNA analysis has practical value in improving the clinical management of advanced biliary tract cancer (BTC) and reveals oncogenic drivers and mechanisms of therapeutic resistance, which are crucial for drug development efforts.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

Results and lessons from dual extraction of DNA and RNA from formalin-fixed paraffin-embedded breast tumor tissues for a large Cancer epidemiologic study

Rochelle Payne Ondracek et al.

Summary: This study reports the results and lessons learned from processing FFPE breast tumor tissues for a large epidemiologic study. The dual DNA/RNA purification using Qiagen AllPrep FFPE extraction protocol is feasible for clinical and epidemiologic studies. The use of tissue punches as a reliable source material and the fine tuning of proteinase K digestion time based on tissue volume are critical for achieving balanced yields of DNA and RNA.

BMC GENOMICS (2022)

Add to Collection

Article Oncology

Precision oncology for intrahepatic cholangiocarcinoma in clinical practice

Aurelie Tomczak et al.

Summary: This study applied molecular profiling of intrahepatic cholangiocarcinoma in combination with a comprehensive umbrella concept in a real-world setting. The analysis showed a detection rate of genetic alterations in 77% of patients and molecular targets in 59% of patients. Patients receiving molecular-matched treatment showed significantly higher survival probability compared to those receiving conventional chemotherapy only.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples

Hatim Husain et al.

Summary: This study examined the use of circulating tumor DNA (ctDNA) in different types of cancers and found that high levels of ctDNA shedding are associated with higher sensitivity and negative predictive value for mutation detection. Liquid biopsies were able to detect potentially targetable gene alterations in various cancer types, and the sensitivity of liquid biopsies varied among different patients.

JCO PRECISION ONCOLOGY (2022)

Add to Collection

Article Hematology

Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma

Maria Cristina Pirosa et al.

Summary: The rapid evolution of genomic technologies has led to the development of different methods for the detection, measurement and analysis of cell-free DNA fragments (cfDNA) shed into the bloodstream. This analysis, known as liquid biopsy, allows for accessing tumor DNA through a simple blood sampling, potentially serving clinical applications in terms of diagnosis, prognosis, and monitoring of minimal residual disease.

HEMASPHERE (2022)

Add to Collection

Article Oncology

Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience

Sabrina Welland et al.

Summary: This study aimed to evaluate the regulatory processes associated with off-label precision oncology treatments and found that a significant subset of GI cancer patients were able to benefit from targeted therapies identified through molecular testing. Despite some rejections, a considerable proportion of patients received targeted therapies and demonstrated treatment efficacy.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

Role of molecular genetics in the clinical management of cholangiocarcinoma

N. Normanno et al.

Summary: Incidence and mortality of cholangiocarcinoma have been increasing, with most patients diagnosed at advanced stages. Targetable genomic alterations have expanded treatment options, emphasizing the importance of early and accurate diagnosis.

ESMO OPEN (2022)

Add to Collection

Article Oncology

Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers

Ryosuke Okamura et al.

Summary: Biliary tract cancers have poor prognoses even with cytotoxic chemotherapy, highlighting the need for precision treatment approaches using comprehensive genomic profiling. Analysis of circulating-tumor DNA (ctDNA) and tissue-based tumor DNA is feasible in these cancers. Molecularly matched therapeutic regimens based on genomic profiling show significantly longer progression-free survival and higher disease control rates compared to unmatched regimens.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers

Wei Zhang et al.

Summary: The study found that NGS-guided targeted therapy and immunotherapy may offer better prognosis for patients with advanced or relapsed biliary tract cancer compared to traditional chemotherapy. The type of gene mutation in patients can guide the selection of appropriate treatment drugs, and TMB is a useful biomarker for predicting the efficacy of immunotherapy.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Urology & Nephrology

Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma

Andrea Necchi et al.

Summary: Differences in the genomic landscapes of UTUC and BUC were modest; however, patients with UTUC were enriched for FGFR3 and HRAS SV relative to BUC.

EUROPEAN UROLOGY FOCUS (2021)

Add to Collection

Article Oncology

Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project

D. M. Vega et al.

Summary: The estimation of TMB varies across different panel assays, with factors like panel size, gene content, and bioinformatics pipelines contributing to empirical variability. Statistical calibration can achieve more consistent results across panels, allowing for comparison of TMB values. A software tool was developed to promote reproducibility and comparability across various assays.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Oncology

Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance

Melanie A. Krook et al.

Summary: FGFRs are aberrantly activated in 5-10% of human cancers through genetic alterations, with FGFR-targeted therapies showing significant advancements in the past decade. However, acquired drug resistance leading to cancer progression remains a challenge in most patients.

BRITISH JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

Ian M. Silverman et al.

Summary: The study utilized genomic profiling data to explore the genomic landscape and molecular diversity of patients with cholangiocarcinoma, as well as analyze the clinicogenomics of patients treated with pemigatinib, highlighting the utility of genomic profiling in clinical trials.

CANCER DISCOVERY (2021)

Add to Collection

Article Oncology

Bile-Based Cell-Free DNA Analysis Is a Reliable Diagnostic Tool in Pancreatobiliary Cancer

Caroline Driescher et al.

Summary: This study demonstrated the feasibility and reliability of bile-derived cfDNA in the diagnosis of pancreatobiliary cancers, showing higher sensitivity compared to plasma and offering a potential alternative when tissue sampling is not feasible.

CANCERS (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Next generation sequencing for biliary tract cancers

Timothy P. DiPeri et al.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Genetics & Heredity

Allelic Dropout Is a Common Phenomenon That Reduces the Diagnostic Yield of PCR-Based Sequencing of Targeted Gene Panels

Anna G. Shestak et al.

Summary: Primary cardiomyopathies are monogenic disorders with multiple alleles influencing pathogenesis. Next-generation sequencing has improved DNA diagnostics but genetic testing for CMPs still has a diagnostic yield below 60%. The study identified allelic dropout as a common issue impacting diagnostic yield in genetic testing for primary cardiomyopathies.

FRONTIERS IN GENETICS (2021)

Add to Collection

Review Oncology

Practical considerations in screening for genetic alterations in cholangiocarcinoma

T. S. Bekaii-Saab et al.

Summary: Cholangiocarcinoma (CCA) is associated with poor outcomes due to aggressive disease progression, late diagnosis, and limited effectiveness of standard chemotherapy. Molecular profiling has revealed diverse genomic alterations as oncogenic drivers, with TP53, CDKN2A/B, and KRAS being the most common genetic alterations in CCA. Intrahepatic CCA (iCCA) and extrahepatic CCA (eCCA) differ substantially in the frequency of genetic alterations, including actionable alterations like IDH1 mutations and FGFR2 rearrangements. Targeted therapies for these alterations provide opportunities for improved treatment plans tailored to the individual patient's genetic signature.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses

Jihoon G. Yoon et al.

Summary: This study identified predictive molecular features of chemotherapy and immunotherapy responses in advanced BTCs using clinical sequencing platforms. The results offer an intuitive framework to guide treatment based on the tumors' molecular features.

HEPATOLOGY (2021)

Add to Collection

Article Oncology

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Angela Lamarca et al.

Summary: This study found that second-line FOLFOX chemotherapy can significantly improve overall survival in patients with advanced biliary tract cancer after progression on cisplatin and gemcitabine, indicating it should be considered as standard-of-care chemotherapy.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer

Q. Gou et al.

Summary: The study demonstrated that bile cell-free DNA (cfDNA) was superior to plasma cfDNA in detecting tumor-related genomic alterations. The sensitivity of CA 19-9 combined with bile cfDNA reached 96.4% in BTC diagnosis, suggesting that bile cfDNA could be a supplemental approach for confirming BTC diagnosis.

ESMO OPEN (2021)

Add to Collection

Article Oncology

Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma

Yuanwen Zheng et al.

Summary: The study identified significant mutational differences between perihilar CCA (pCCA) and distal CCA (dCCA) within extrahepatic CCA (exCCA), leading to different prognoses. Additionally, certain gene mutations were found to be associated with tumor mutational burden (TMB), potentially serving as biomarkers for treatment prediction.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Next-Generation Biomarkers for Cholangiocarcinoma

Pedro M. Rodrigues et al.

Summary: The early and non-invasive diagnosis of cholangiocarcinoma (CCA) remains a challenge, contributing to increased mortality rates globally. Efforts to identify novel biomarkers for CCA diagnosis and prognosis prediction are ongoing, with the hope of improving patient outcomes in the future. High-throughput omics-based approaches hold promise for identifying circulating biomarkers that may aid in early detection and treatment stratification in large-scale validation studies.

CANCERS (2021)

Add to Collection

Article Oncology

Liquid Biopsy from Bile-Circulating Tumor DNA in Patients with Biliary Tract Cancer

Jin-Yi Han et al.

Summary: Utilization of cell free DNA from bile fluid shows promising potential for diagnosing and monitoring patients with biliary tract cancers, with mutational variants reliably detected and showing a strong positive correlation with tissue samples, suggesting bile as an effective biopsy fluid for ctDNA analysis.

CANCERS (2021)

Add to Collection

Review Oncology

Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review

Rohan Shotton et al.

Summary: Biliary tract cancer is a rare entity outside high-endemic areas, with most patients presenting at a late stage and having poor prognosis. Liquid biopsies offer a safe and convenient alternative for histological diagnosis, and have potential as diagnostic, predictive, and prognostic biomarkers.

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

Add to Collection

Review Pathology

Cholangiocarcinoma

Samantha Sarcognato et al.

Summary: Liver cancer is the third leading cause of cancer-related death worldwide. Cholangiocarcinoma (CCA) is the second most common type of liver cancer, with increasing incidence and mortality. Most CCAs are diagnosed at an advanced stage with limited treatment options, and they can be classified into intrahepatic, perihilar, and distal CCA.

PATHOLOGICA (2021)

Add to Collection

Article Biochemical Research Methods

Probe design for simultaneous, targeted capture of diverse metagenomic targets

Zachery W. Dickson et al.

Summary: The HUBDesign pipeline addresses the challenges of low signal, high background, and uncertain targets in metagenomic sequencing efforts by utilizing sequence homology to design probes at multiple taxonomic levels. The system efficiently captures known and related sequences, such as the breadth of coronavirus diversity and bacterial pathogens underlying sepsis, demonstrating significant enrichment in separate experiments.

CELL REPORTS METHODS (2021)

Add to Collection

Review Gastroenterology & Hepatology

Cell of origin in biliary tract cancers and clinical implications

Agrin Moeini et al.

Summary: Biliary tract cancers (BTCs) are aggressive epithelial malignancies with rising incidence and mortality rates, emphasizing the need for improved diagnostic and therapeutic strategies. BTCs exhibit high inter- and intra-tumour heterogeneity at both morphological and molecular levels. Recent research has focused on histopathological subtyping and the cell of origin of these tumors, highlighting distinct molecular alterations and potential cells of origin.

JHEP REPORTS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures

Aatur D. Singhi et al.

GUT (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Clinical and Translational Research Challenges in Biliary Tract Cancers

Angela Lamarca et al.

CURRENT MEDICINAL CHEMISTRY (2020)

Add to Collection

Review Gastroenterology & Hepatology

Molecular classification of cholangiocarcinoma

Corentin Louis et al.

CURRENT OPINION IN GASTROENTEROLOGY (2020)

Add to Collection

Review Pathology

The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology

Xavier Matias-Guiu et al.

VIRCHOWS ARCHIV (2020)

Add to Collection

Article Oncology

Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications

Raffaella Pasquale et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2020)

Add to Collection

Review Gastroenterology & Hepatology

Molecular targeted therapies: Ready for prime time in biliary tract cancer

Angela Lamarca et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

Robert Montal et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Genetics & Heredity

A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer

Alex H. Wagner et al.

NATURE GENETICS (2020)

Add to Collection

Review Medicine, General & Internal

Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review

Rossella Bruno et al.

DIAGNOSTICS (2020)

Add to Collection

Review Cell Biology

Why Formalin-fixed, Paraffin-embedded Biospecimens Must Be Used in Genomic Medicine: An Evidence-based Review and Conclusion

William Mathieson et al.

JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Jesus M. Banales et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention

Antonella De Luca et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Article Medicine, General & Internal

Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers

Angela Lamarca et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Pathology

Pathogenesis of Cholangiocarcinoma

Pedro M. Rodrigues et al.

Annual Review of Pathology-Mechanisms of Disease (2020)

Add to Collection

Article Oncology

Collaborative, Multidisciplinary Evaluation of Cancer Variants Through Virtual Molecular Tumor Boards Informs Local Clinical Practices

Shruti Rao et al.

JCO CLINICAL CANCER INFORMATICS (2020)

Add to Collection

Article Multidisciplinary Sciences

Paired rRNA-depleted and polyA-selected RNA sequencing data and supporting multi-omics data from human T cells

Li Chen et al.

SCIENTIFIC DATA (2020)

Add to Collection

Review Oncology

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

F. Mosele et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

Whole-Genome Sequencing in Cancer

Eric Y. Zhao et al.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2019)

Add to Collection

Article Oncology

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer

Alexa B. Schrock et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection

Review Gastroenterology & Hepatology

Anatomical, histomorphological and molecular classification of cholangiocarcinoma

Timothy Kendall et al.

LIVER INTERNATIONAL (2019)

Add to Collection

Review Gastroenterology & Hepatology

Clinical presentation, diagnosis and staging of cholangiocarcinoma

Alejandro Forner et al.

LIVER INTERNATIONAL (2019)

Add to Collection

Article Oncology

TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma

Lipika Goyal et al.

CANCER DISCOVERY (2019)

Add to Collection

Article Oncology

An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer

Brian C. Haynes et al.

TRANSLATIONAL ONCOLOGY (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Applications and analysis of targeted genomic sequencing in cancer studies

Findlay Bewicke-Copley et al.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2019)

Add to Collection

Article Cell Biology

National Cancer Institute Biospecimen Evidence-Based Practices: Harmonizing Procedures for Nucleic Acid Extraction from Formalin-Fixed, Paraffin-Embedded Tissue

Sarah R. Greytak et al.

BIOPRESERVATION AND BIOBANKING (2018)

Add to Collection

Article Biotechnology & Applied Microbiology

Unique, dual-indexed sequencing adapters with UMIs effectively eliminate index crosstalk and significantly improve sensitivity of massively parallel sequencing

Laura E. MacConaill et al.

BMC GENOMICS (2018)

Add to Collection

Article Oncology

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention

Maeve A. Lowery et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Oncology

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus

Alexa B. Schrock et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Pathology

Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management

Stacy S. Hung et al.

JOURNAL OF MOLECULAR DIAGNOSTICS (2018)

Add to Collection

Article Surgery

Comparison of biliary brush biopsy and fine needle biopsy in the diagnosis of biliary strictures

Adrian Gonzalez-Aguirre et al.

MINIMALLY INVASIVE THERAPY & ALLIED TECHNOLOGIES (2018)

Add to Collection

Article Multidisciplinary Sciences

Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform

Scott Morris et al.

PLOS ONE (2018)

Add to Collection

Article Cell Biology

National Cancer Institute Biospecimen Evidence-Based Practices: Harmonizing Procedures for Nucleic Acid Extraction from Formalin-Fixed, Paraffin-Embedded Tissue

Sarah R. Greytak et al.

BIOPRESERVATION AND BIOBANKING (2018)

Add to Collection

Article Oncology

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

J. Mateo et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Cell Biology

Enhanced detection of circulating tumor DNA by fragment size analysis

Florent Mouliere et al.

SCIENCE TRANSLATIONAL MEDICINE (2018)

Add to Collection

Article Gastroenterology & Hepatology

Usefulness of cholangioscopic-guided mapping biopsy using SpyGlass DS for preoperative evaluation of extrahepatic cholangiocarcinoma: a pilot study

Takahisa Ogawa et al.

ENDOSCOPY INTERNATIONAL OPEN (2018)

Add to Collection

Review Pathology

A Next-Generation Sequencing PrimerHow Does It Work and What Can It Do?

Yuriy O. Alekseyev et al.

ACADEMIC PATHOLOGY (2018)

Add to Collection

Review Pathology

Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL

Zandra C. Deans et al.

VIRCHOWS ARCHIV (2017)

Add to Collection

Article Oncology

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma

Lipika Goyal et al.

CANCER DISCOVERY (2017)

Add to Collection

Article Oncology

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial

Loic Verlingue et al.

EUROPEAN JOURNAL OF CANCER (2017)

Add to Collection

Article Pathology

Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists

Lawrence J. Jennings et al.

JOURNAL OF MOLECULAR DIAGNOSTICS (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Ahmet Zehir et al.

NATURE MEDICINE (2017)

Add to Collection

Article Pharmacology & Pharmacy

Clinical application of a cancer genomic profiling assay to guide precision medicine decisions

Cheryl Eifert et al.

PERSONALIZED MEDICINE (2017)

Add to Collection

Article Oncology

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma

Apinya Jusakul et al.

CANCER DISCOVERY (2017)

Add to Collection

Article Oncology

Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences

Minho Cho et al.

ONCOTARGET (2017)

Add to Collection

Article Oncology

Genomic Profiling of Small-Bowel Adenocarcinoma

Alexa B. Schrock et al.

JAMA ONCOLOGY (2017)

Add to Collection

Article Oncology

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer

J. H. Chung et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Article Biotechnology & Applied Microbiology

Detecting very low allele fraction variants using targeted DNA sequencing and a novel molecular barcode-aware variant caller

Chang Xu et al.

BMC GENOMICS (2017)

Add to Collection

Article Pathology

Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets

Hwajeong Lee et al.

JOURNAL OF CLINICAL PATHOLOGY (2016)

Add to Collection

Review Medical Laboratory Technology

Next-Generation Sequencing Informatics Challenges and Strategies for Implementation in a Clinical Environment

Somak Roy et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)

Add to Collection

Article Oncology

Biliary Cancer: Utility of Next-Generation Sequencing for Clinical Management

Milind Javle et al.

CANCER (2016)

Add to Collection

Editorial Material Pathology

Next-Generation Sequencing in Cancer Diagnostics

Christopher L. Corless

JOURNAL OF MOLECULAR DIAGNOSTICS (2016)

Add to Collection

Article Oncology

Digitally guided microdissection aids somatic mutation detection in difficult to dissect tumors

Katherine Geiersbach et al.

CANCER GENETICS (2016)

Add to Collection

Article Oncology

Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma

Anna Maria Rachiglio et al.

ONCOTARGET (2016)

Add to Collection

Article Oncology

Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium

Bastiaan B. J. Tops et al.

BMC CANCER (2015)

Add to Collection

Article Genetics & Heredity

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

Sue Richards et al.

GENETICS IN MEDICINE (2015)

Add to Collection

Article Genetics & Heredity

Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing

Eric Samorodnitsky et al.

HUMAN MUTATION (2015)

Add to Collection

Review Medical Laboratory Technology

Sequence Artifacts in DNA from Formalin-Fixed Tissues: Causes and Strategies for Minimization

Hongdo Do et al.

CLINICAL CHEMISTRY (2015)

Add to Collection

Article Oncology

Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing

Carolyn J. Shiau et al.

JOURNAL OF THORACIC ONCOLOGY (2014)

Add to Collection

Article Pathology

The estimation of tumor cell percentage for molecular testing by pathologists is not accurate

Alexander J. J. Smits et al.

MODERN PATHOLOGY (2014)

Add to Collection

© Peeref 2019-2024. All rights reserved.